Objective:Clinical use of stimulator of interferon genes(STING)agonists has challenges due to poor responsiveness and variable efficacy.Therefore,identifying tumor types that are sensitive to these agents and clarifyi...Objective:Clinical use of stimulator of interferon genes(STING)agonists has challenges due to poor responsiveness and variable efficacy.Therefore,identifying tumor types that are sensitive to these agents and clarifying the underlying mechanisms are essential.Methods:In vitro screening was performed to identify tumor types that are sensitive to STING agonists.The non-nucleotide agonist,SR-717,and the macrocyclic agonist,E7766,were compared for efficacy.Complementary in vivo and in vitro studies,including gene-knockout models,HMGN2-knockout Neuro-2A and CT-2A cells apoptosis assays,and murine tumor models,were then performed.These experiments focused on the mechanism by which SR-717 mediates antitumor effects and emphasized the role of STING signaling-induced high-mobility group nucleosome-binding protein 2(HMGN2).In addition,the potential of HMGN2 as a prognostic biomarker was assessed.Results:Neuroblastomas and glioblastomas,two nervous system tumors,were shown to be sensitive to STING agonists.SR-717 exhibited greater antitumor efficacy compared to E7766.Mechanistic studies indicated that STING agonists promote apoptosis through activation of the intrinsic STING-signal transducer and activator of transcription 1(STAT1)-HMGN2 axis within tumor cells.Ectopic expression of HMGN2 in melanoma cells,which naturally lack HMGN2,led to significant apoptosis.Furthermore,analysis of The Cancer Genome Atlas and Gene Expression Omnibus databases revealed positive correlation between elevated HMGN2 expression and patient survival,supporting the utility of HMGN2 as a prognostic biomarker.Conclusions:This study clarified the mechanism underlying the potent antitumor activity of SR-717 in nervous system tumors through activation of the STING-STAT1-HMGN2 signaling pathway and demonstrated that SR-717 has superior efficacy compared to E7766.In addition,HMGN2 was shown to exhibit translational potential as a prognostic biomarker for patient survival.展开更多
目的:分离纯化鉴定兔高迁移率非组蛋白N2(High mobility group chromosomal protein N2,HMGN2)。方法:利用液氮研磨和5%高氯酸从新鲜兔胸腺组织获得酸溶性萃取物,经反相高效液相色谱(RP-HPLC)分离得到HMGN2,经过SDS-聚丙烯酰胺凝胶电泳...目的:分离纯化鉴定兔高迁移率非组蛋白N2(High mobility group chromosomal protein N2,HMGN2)。方法:利用液氮研磨和5%高氯酸从新鲜兔胸腺组织获得酸溶性萃取物,经反相高效液相色谱(RP-HPLC)分离得到HMGN2,经过SDS-聚丙烯酰胺凝胶电泳和Western-blotting对HMGN2进行分子量测定和特异性鉴定。并利用琼脂糖弥散抑菌实验对其杀菌活性进行鉴定。结果:利用上述方法分离纯化出高纯度的兔HMGN2。对大肠埃希菌临床分离株54080、大肠埃希菌ATCC25922有明显杀菌活性。结论:建立简单分离高纯度的HMGN2的方法。展开更多
目的:我们先前的研究证明HMGN2(high mobility group nucleosomal-binding domain2)是人LAK细胞抗菌的一个新的效应分子,本研究欲检测其体外抗乙型肝炎病毒的活性。方法:应用反向高效液相色谱技术从人淋巴结组织酸溶性提取物中分离纯化...目的:我们先前的研究证明HMGN2(high mobility group nucleosomal-binding domain2)是人LAK细胞抗菌的一个新的效应分子,本研究欲检测其体外抗乙型肝炎病毒的活性。方法:应用反向高效液相色谱技术从人淋巴结组织酸溶性提取物中分离纯化批量HMGN2分子,用质谱精确分子量测定、Western blotting和抗菌试验对分离纯化得到的HMGN2分子进行分子鉴定。采用MTT法检测HMGN2分子对稳定转染复制型HBV重组质粒的肝胚瘤细胞株HepG2.2.15细胞的细胞毒性;用不同浓度HMGN2分子作用于HepG2.2.15细胞,分别在第3d和第6d收集细胞培养上清液,ELISA检测上清中HBV表面抗原(HBsAg)及e抗原(HBeAg),采用实时荧光定量PCR法检测上清液HBVDNA的含量。结果:从人淋巴结组织中分离纯化获得纯度较高的HMGN2蛋白;在检1-100mg/L范围内,HMGN2分子对HepG2.2.15细胞无细胞毒性;HMGN2分子在1-5mg/L水平即可显著抑制HBeAg和HBsAg的表达,可显著降低HBVDNA拷贝数。结论:HMGN2分子在体外具有较强的抗HBV活性。展开更多
文摘Objective:Clinical use of stimulator of interferon genes(STING)agonists has challenges due to poor responsiveness and variable efficacy.Therefore,identifying tumor types that are sensitive to these agents and clarifying the underlying mechanisms are essential.Methods:In vitro screening was performed to identify tumor types that are sensitive to STING agonists.The non-nucleotide agonist,SR-717,and the macrocyclic agonist,E7766,were compared for efficacy.Complementary in vivo and in vitro studies,including gene-knockout models,HMGN2-knockout Neuro-2A and CT-2A cells apoptosis assays,and murine tumor models,were then performed.These experiments focused on the mechanism by which SR-717 mediates antitumor effects and emphasized the role of STING signaling-induced high-mobility group nucleosome-binding protein 2(HMGN2).In addition,the potential of HMGN2 as a prognostic biomarker was assessed.Results:Neuroblastomas and glioblastomas,two nervous system tumors,were shown to be sensitive to STING agonists.SR-717 exhibited greater antitumor efficacy compared to E7766.Mechanistic studies indicated that STING agonists promote apoptosis through activation of the intrinsic STING-signal transducer and activator of transcription 1(STAT1)-HMGN2 axis within tumor cells.Ectopic expression of HMGN2 in melanoma cells,which naturally lack HMGN2,led to significant apoptosis.Furthermore,analysis of The Cancer Genome Atlas and Gene Expression Omnibus databases revealed positive correlation between elevated HMGN2 expression and patient survival,supporting the utility of HMGN2 as a prognostic biomarker.Conclusions:This study clarified the mechanism underlying the potent antitumor activity of SR-717 in nervous system tumors through activation of the STING-STAT1-HMGN2 signaling pathway and demonstrated that SR-717 has superior efficacy compared to E7766.In addition,HMGN2 was shown to exhibit translational potential as a prognostic biomarker for patient survival.
文摘目的:分离纯化鉴定兔高迁移率非组蛋白N2(High mobility group chromosomal protein N2,HMGN2)。方法:利用液氮研磨和5%高氯酸从新鲜兔胸腺组织获得酸溶性萃取物,经反相高效液相色谱(RP-HPLC)分离得到HMGN2,经过SDS-聚丙烯酰胺凝胶电泳和Western-blotting对HMGN2进行分子量测定和特异性鉴定。并利用琼脂糖弥散抑菌实验对其杀菌活性进行鉴定。结果:利用上述方法分离纯化出高纯度的兔HMGN2。对大肠埃希菌临床分离株54080、大肠埃希菌ATCC25922有明显杀菌活性。结论:建立简单分离高纯度的HMGN2的方法。
